Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates. - Wikidata - wikimedia - TriplyDB

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

http://www.wikidata.org/entity/Q35230144

about

The dichotomous role of H2S in cancer cell biology? Déjà vu all over again.Glutathione S -transferase π: a potential role in antitumor therapy

P2860

Q49346285-3954C897-4C28-4F03-B95B-0A9807E68411 Q58694500-2E1CCF7C-FB6C-414D-8796-5E932BC174AC

P2860

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

http://www.wikidata.org/entity/Q35230144

description

2010 nî lūn-bûn

@nan

2010 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@ast

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@en

type

label

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@ast

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@en

prefLabel

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@ast

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@en

P1433

Q35230144-46E98A4A-1A4D-4C51-9988-C86FACB83FC2

P1476

Q35230144-838496BB-BB49-494F-A7DF-CCB4F2F5F4EC

P2093

Q35230144-AF8CF918-F134-48FB-9F67-43B0E0CAC804

Q35230144-FFB2A05E-246D-4CF9-83CA-8088AE14C463

P2860

Q35230144-1F76F45E-9EB7-49CE-A1FE-D7E61F73B3F5

Q35230144-37FB538A-4714-45D1-BFA7-D362CA15884B

Q35230144-46B62A4B-D108-4CFF-AEDA-686E1E5A1FE5

Q35230144-62160EA8-DAE2-470D-91FF-2D5F3F4B366D

Q35230144-6669525A-9021-4501-8E86-A6A1EF11041A

Q35230144-6AEBD1F8-DCCC-4506-AEB8-9F96CE7763DC

Q35230144-87C095B6-2176-4C02-8431-23DAA84A1435

Q35230144-94F8846E-9FB3-414C-8555-2F10BD5D1646

Q35230144-9AA9EC5B-2226-4298-8554-8ECFC5DFA8DD

Q35230144-AE6F715B-DC36-4F98-8F37-B63BE2C1ED58

P304

Q35230144-AD694A85-F681-4B74-A950-6D8C1D5A3C04

P31

Q35230144-250D7A33-1747-4B21-B340-25A66D743EF4

P356

Q35230144-B62A0634-B4C0-466A-B580-17D21E60084E

P433

Q35230144-AB15D69A-1626-4DE4-9581-57CA646E005C

P478

Q35230144-CBB43965-D4D2-4CD4-B049-80F0FD0E3FBF

P577

Q35230144-F2340EE2-CCF7-4987-9030-7C34A1DAB9A4

P698

Q35230144-4673AAB7-1FC0-4989-B7C4-B4F5C8286C65

P932

Q35230144-0F44F66F-93F4-496B-A9FF-9BD5EC4E138B

P356

FORUMIMMUNDISTHER.V1.I3.30

P1433

Forum on Immunopathological Diseases and Therapeutics

P1476

Broad-Spectrum Anti-Cancer Activity of O-Arylated Diazeniumdiolates.

@en

P2093

Larry K Keefer

http://www.w3.org/2001/XMLSchema#string

behalf of the JS-K Consortium

http://www.w3.org/2001/XMLSchema#string

P2860

Nitric oxide prodrug JS-K inhibits ubiquitin E1 and kills tumor cells retaining wild-type p53

JS-K has potent anti-angiogenic activity in vitro and inhibits tumour angiogenesis in a multiple myeloma model in vivo.

JS-K, a GST-activated nitric oxide generator, induces DNA double-strand breaks, activates DNA damage response pathways, and induces apoptosis in vitro and in vivo in human multiple myeloma cells.

Gene expression profiling for nitric oxide prodrug JS-K to kill HL-60 myeloid leukemia cells.

TIMP-2 mediates the anti-invasive effects of the nitric oxide-releasing prodrug JS-K in breast cancer cells

Synthesis, mechanistic studies, and anti-proliferative activity of glutathione/glutathione S-transferase-activated nitric oxide prodrugs.

JS-K, an arylating nitric oxide (NO) donor, has synergistic anti-leukemic activity with cytarabine (ARA-C).

Antitumor activity of JS-K [O2-(2,4-dinitrophenyl) 1-[(4-ethoxycarbonyl)piperazin-1-yl]diazen-1-ium-1,2-diolate] and related O2-aryl diazeniumdiolates in vitro and in vivo.

PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity.

Nitric oxide prodrugs and metallochemotherapeutics: JS-K and CB-3-100 enhance arsenic and cisplatin cytolethality by increasing cellular accumulation.

P304

205-218

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1615/FORUMIMMUNDISTHER.V1.I3.30

http://www.w3.org/2001/XMLSchema#string

P433

3

http://www.w3.org/2001/XMLSchema#string

P478

1

http://www.w3.org/2001/XMLSchema#string

P577

2010-07-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21949595

http://www.w3.org/2001/XMLSchema#string

P932

3179376

http://www.w3.org/2001/XMLSchema#string